Dance Biopharm Status
The company received $24.5 million of development capital from Molex Ventures and other undisclosed investors on September 19, 2018. The funding enables the company to support human clinical studies and manufacture drug and devices for clinical studies.
Leave a Reply ·
You must be logged in to post a comment.